StreetInsider.com News Articles

Form 4 Edgewise Therapeutics, For: Jun 05 Filed by: ROOT JONATHAN D

Fri, 17 Jul 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260717/26784665.html

Form 4 Edgewise Therapeutics, For: Jun 05 Filed by: ROOT JONATHAN D

Fri, 17 Jul 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260717/26784665.html

Form 8-K/A Edgewise Therapeutics, For: Jul 10

Thu, 16 Jul 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260716/26776961.html

Form 8-K/A Edgewise Therapeutics, For: Jul 10

Thu, 16 Jul 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260716/26776961.html

Form 8-K Edgewise Therapeutics, For: Jul 10

Mon, 13 Jul 2026 08:37:00 -0400

si-local-file:///var/storage/secattach/20260713/26760340.html

Form 8-K Edgewise Therapeutics, For: Jul 10

Mon, 13 Jul 2026 08:37:00 -0400

si-local-file:///var/storage/secattach/20260713/26760340.html

Edgewise sells muscular dystrophy drug to Servier for up to $2.65B

Mon, 13 Jul 2026 08:30:55 -0400

Edgewise Therapeutics (Nasdaq: EWTX) has completed the sale of sevasemten and its muscular dystrophy business to Servier, an independent international pharmaceutical group, for $1.55 billion in upfront cash and up to $1.1 billion in regulatory and commercial milestone payments, bringing potential total consideration to $2.65 billion.

Under the terms of the deal, Servier acquired all rights to sevasemten, including related intellectual property, regulatory filings, and clinical data. Edgewise employees primarily supporting the muscular dystrophy business received offers to transition to Servier.

Edgewise said it expects the upfront proceeds, combined with its existing cash, to fully fund development of its lead cardiovascular candidate,

Edgewise sells muscular dystrophy drug to Servier for up to $2.65B

Mon, 13 Jul 2026 08:30:55 -0400

Edgewise said it expects the upfront proceeds, combined with its existing cash, to fully fund development of its lead cardiovascular candidate,

Edgewise sells muscular dystrophy drug to Servier for up to $2.65B

Mon, 13 Jul 2026 08:30:55 -0400

Edgewise said it expects the upfront proceeds, combined with its existing cash, to fully fund development of its lead cardiovascular candidate,

Edgewise sells muscular dystrophy drug to Servier for up to $2.65B

Mon, 13 Jul 2026 08:30:55 -0400

Edgewise said it expects the upfront proceeds, combined with its existing cash, to fully fund development of its lead cardiovascular candidate,

Edgewise sells muscular dystrophy drug to Servier for up to $2.65B

Mon, 13 Jul 2026 08:30:55 -0400

Edgewise said it expects the upfront proceeds, combined with its existing cash, to fully fund development of its lead cardiovascular candidate,

Edgewise sells muscular dystrophy drug to Servier for up to $2.65B

Mon, 13 Jul 2026 08:30:55 -0400

Edgewise said it expects the upfront proceeds, combined with its existing cash, to fully fund development of its lead cardiovascular candidate,

Edgewise sells muscular dystrophy drug to Servier for up to $2.65B

Mon, 13 Jul 2026 08:30:55 -0400

Edgewise said it expects the upfront proceeds, combined with its existing cash, to fully fund development of its lead cardiovascular candidate,

Servier buys Edgewise muscular dystrophy unit for up to $2.65B

Mon, 13 Jul 2026 08:30:42 -0400

Servier, a French pharmaceutical group, has completed its acquisition of the muscular dystrophy business of Edgewise Therapeutics (Nasdaq: EWTX) for up to $2.65 billion, according to a press release from the company.

The deal includes an upfront payment of $1.55 billion and up to $1.1 billion in regulatory and commercial milestone payments. The transaction closed following regulatory clearance and customary closing conditions.

The acquisition gives Servier control of sevasemten, an investigational oral drug described as a potential first-in-class fast skeletal myosin inhibitor. The compound is currently being evaluated in a pivotal cohort for Becker muscular dystrophy (BMD) and in a phase 2

Servier buys Edgewise muscular dystrophy unit for up to $2.65B

Mon, 13 Jul 2026 08:30:42 -0400

Servier buys Edgewise muscular dystrophy unit for up to $2.65B

Mon, 13 Jul 2026 08:30:42 -0400

Servier buys Edgewise muscular dystrophy unit for up to $2.65B

Mon, 13 Jul 2026 08:30:42 -0400

Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline

Mon, 13 Jul 2026 08:30:00 -0400

— Edgewise receives $1.55 billion in upfront cash and is eligible to receive up to $1.1 billion in regulatory and commercial milestones —

— Transaction creates strategically focused cardiovascular company —